| EMA number | EMEA/H/C/002332 |
| ATC code | J05AE |
| Authorisation | 18 July 2011 |
| Withdrawn | 29 June 2018 |
| Revision | 22 |
Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.